{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:38:09Z","timestamp":1790746689672,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research and development project of Affiliated Hospital of North Sichuan Medical College","award":["2022LC001"],"award-info":[{"award-number":["2022LC001"]}]},{"name":"Research and development project of Affiliated Hospital of North Sichuan Medical College","award":["2022LC004"],"award-info":[{"award-number":["2022LC004"]}]},{"name":"Opening Project of Medical Imaging Key Laboratory of Sichuan Province","award":["MIKL202409"],"award-info":[{"award-number":["MIKL202409"]}]},{"name":"Nanchong science and technology plan project","award":["23JCYJPT0062"],"award-info":[{"award-number":["23JCYJPT0062"]}]},{"name":"Sichuan Science and Technology Program","award":["2024NSFSC0668"],"award-info":[{"award-number":["2024NSFSC0668"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-98757-8","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:14:25Z","timestamp":1745543665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical and clinical evaluation of [64Cu]Cu-PSMA-Q PET\/CT for prostate cancer detection and its comparison with [18F]FDG imaging"],"prefix":"10.1038","volume":"15","author":[{"given":"Fei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tielong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-4265","authenticated-orcid":false,"given":"Suping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"98757_CR1","unstructured":"World Cancer Research Fund. Prostate cancer statistics. https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/prostate-cancer-statistics\/. (Accessed 7 Jan 2025). (2024)."},{"issue":"1","key":"98757_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7150\/jca.7709","volume":"5","author":"TJ Wallace","year":"2014","unstructured":"Wallace, T. J. et al. Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J. Cancer 5(1), 3\u201324 (2014).","journal-title":"J. Cancer"},{"issue":"1","key":"98757_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/fon-2022-0891","volume":"19","author":"JR Vazquez-Urrutia","year":"2023","unstructured":"Vazquez-Urrutia, J. R., Torres-Bustamante, M. I., Cerda-Cruz, C. R., Bravo-Cuellar, A. & Ortiz-Lazareno, P. C. The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review. Future Oncol. 19(1), 77\u201393 (2023).","journal-title":"Future Oncol."},{"issue":"24","key":"98757_CR4","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler, W. P. et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin. Cancer Res. 25(24), 7448\u20137454 (2019).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"98757_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13014-020-01519-1","volume":"15","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer, M. et al. Recent advances of PET imaging in clinical radiation oncology. Radiat. Oncol. 15(1), 88 (2020).","journal-title":"Radiat. Oncol."},{"issue":"3","key":"98757_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.apsb.2022.07.018","volume":"13","author":"LL Wu","year":"2023","unstructured":"Wu, L. L. et al. Membrane dual-targeting probes: A promising strategy for fluorescence-guided prostate cancer surgery and lymph node metastases detection. Acta Pharm. Sin. B 13(3), 1204\u20131215 (2023).","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"98757_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/cancers14051169","volume":"14","author":"WI Luining","year":"2022","unstructured":"Luining, W. I. et al. Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer. Cancers 14(5), 1169 (2022).","journal-title":"Cancers"},{"key":"98757_CR8","doi-asserted-by":"publisher","first-page":"175883592311822","DOI":"10.1177\/17588359231182293","volume":"15","author":"M Uemura","year":"2023","unstructured":"Uemura, M. et al. The current status of prostate cancer treatment and PSMA theranostics. Ther. Adv. Med. Oncol. 15, 17588359231182292 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"98757_CR9","first-page":"227","volume":"53","author":"RS Israeli","year":"1993","unstructured":"Israeli, R. S., Powell, C. T., Fair, W. R. & Heston, W. D. W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Can. Res. 53(2), 227\u2013230 (1993).","journal-title":"Can. Res."},{"issue":"16","key":"98757_CR10","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3390\/cancers13164023","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang, H., Koumna, S., Pouliot, F., Beauregard, J. M. & Kolinsky, M. PSMA theranostics: Current landscape and future outlook. Cancers 13(16), 4023 (2021).","journal-title":"Cancers"},{"issue":"4","key":"98757_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.semnuclmed.2024.02.003","volume":"54","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem, A., Zimmermann, R., Abdlkadir, A. S. & Herrmann, K. Radiotheranostics global market and future developments. Semin. Nucl. Med. 54(4), 622\u2013633 (2024).","journal-title":"Semin. Nucl. Med."},{"key":"98757_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s13629-020-00296-6","volume":"10","author":"M Wondergem","year":"2020","unstructured":"Wondergem, M., van der Zant, F. M., Broos, W. A. M. & Knol, R. J. J. Clinical impact of PSMA PET in biochemically recurrent prostate cancer; a review of the literature. Tijdschr. Voor Urol. 10, 109\u2013121 (2020).","journal-title":"Tijdschr. Voor Urol."},{"issue":"1","key":"98757_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/rg.2019180079","volume":"39","author":"FG Barbosa","year":"2019","unstructured":"Barbosa, F. G. et al. Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread. Radiographics 39(1), 186\u2013212 (2019).","journal-title":"Radiographics"},{"issue":"1","key":"98757_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach, P. J. et al. The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J. Nucl. Med. 59(1), 82\u201388 (2018).","journal-title":"J. Nucl. Med."},{"issue":"9","key":"98757_CR15","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil, C. et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur. J. Nucl. Med. Mol. Imaging. 50(9), 2830\u20132845 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"5","key":"98757_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2967\/jnumed.117.190157","volume":"58","author":"C Kesch","year":"2017","unstructured":"Kesch, C., Kratochwil, C., Mier, W., Kopka, K. & Giesel, F. L. 68Ga or 18F for prostate cancer imaging?. J. Nucl. Med. 58(5), 687\u2013688 (2017).","journal-title":"J. Nucl. Med."},{"issue":"12","key":"98757_CR17","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.3390\/ijms21124309","volume":"21","author":"J-K Yoon","year":"2020","unstructured":"Yoon, J.-K., Park, B.-N., Ryu, E.-K., An, Y.-S. & Lee, S.-J. Current perspectives on 89Zr-PET imaging. Int. J. Mol. Sci. 21(12), 4309 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"98757_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.euo.2018.12.007","volume":"2","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck, T. et al. Validation of the decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery. Eur. Urol. Oncol. 2(5), 589\u2013596 (2019).","journal-title":"Eur. Urol. Oncol."},{"issue":"9","key":"98757_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20(9), 1286\u20131294 (2019).","journal-title":"Lancet Oncol."},{"issue":"8","key":"98757_CR20","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1007\/s00259-022-05775-z","volume":"49","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 49(8), 2774\u20132785 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"98757_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/ph15081001","volume":"15","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Optimized 68Ga-labeled urea-based PSMA-targeted PET tracers for prostate cancer. Pharmaceuticals 15(8), 1001 (2022).","journal-title":"Pharmaceuticals"},{"key":"98757_CR22","unstructured":"Chinese Pharmacopoeia Commission. (2020). Chinese Pharmacopoeia (2020 Edition, Part IV, pp. 537). China Medical Science Press."},{"key":"98757_CR23","unstructured":"Former China Food and Drug Administration. Quality control guidelines for positron radiopharmaceuticals. ChemLinked BaiPharm. https:\/\/baipharm.chemlinked.com\/regulatorydb\/view\/164. (2004)."},{"key":"98757_CR24","first-page":"785","volume":"784","author":"S Shah","year":"2022","unstructured":"Shah, S. Common terminology criteria for adverse events. Natl. Cancer Inst. USA 784, 785 (2022).","journal-title":"Natl. Cancer Inst. USA"},{"issue":"7","key":"98757_CR25","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.ejrad.2014.03.024","volume":"83","author":"M Micc\u00f2","year":"2014","unstructured":"Micc\u00f2, M. et al. Combined pre-treatment MRI and 18F-FDG PET\/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur. J. Radiol. 83(7), 1169\u20131176 (2014).","journal-title":"Eur. J. Radiol."},{"key":"98757_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny, C. et al. 68 Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur. J. Nucl. Med. Mol. Imaging 44, 941\u2013949 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"98757_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber, M. et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 56(5), 668\u2013674 (2015).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"98757_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2967\/jnumed.119.229187","volume":"61","author":"I Rauscher","year":"2020","unstructured":"Rauscher, I. et al. Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J. Nucl. Med. 61(1), 51\u201357 (2020).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"98757_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1148\/radiol.2511081300","volume":"251","author":"B Huang","year":"2009","unstructured":"Huang, B., Law, M. W. M. & Khong, P.-L. Whole-body PET\/CT scanning: estimation of radiation dose and cancer risk. Radiology 251(1), 166\u2013174 (2009).","journal-title":"Radiology"},{"issue":"13","key":"98757_CR30","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1007\/s00259-021-05426-9","volume":"48","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 48(13), 4508\u20134516 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"98757_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","volume":"57","author":"IJ Liu","year":"2001","unstructured":"Liu, I. J., Zafar, M. B., Lai, Y.-H., Segall, G. M. & Terris, M. K. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57(1), 108\u2013111 (2001).","journal-title":"Urology"},{"issue":"5","key":"98757_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/028418602320405005","volume":"41","author":"E Salminen","year":"2002","unstructured":"Salminen, E., Hogg, A., Binns, D., Frydenberg, M. & Hicks, R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 41(5), 425\u2013429 (2002).","journal-title":"Acta Oncol."},{"issue":"5","key":"98757_CR33","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers15051376","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard, C. et al. Detection efficacy of 68Ga-PSMA-11 PET\/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-year, two-center \u201creal-world\u201d experience. Cancers 15(5), 1376 (2023).","journal-title":"Cancers"},{"issue":"7","key":"98757_CR34","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00259-023-06136-0","volume":"50","author":"A Basso Dias","year":"2023","unstructured":"Basso Dias, A. et al. The role of [18F]-DCFPyL PET\/MRI radiomics for pathological grade group prediction in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 50(7), 2167\u20132176 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"98757_CR35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh, A. et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J. Nucl. Med. 56(11), 1697\u20131705 (2015).","journal-title":"J. Nucl. Med."},{"issue":"4","key":"98757_CR36","first-page":"379","volume":"24","author":"CJ Anderson","year":"2009","unstructured":"Anderson, C. J. & Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24(4), 379\u2013393 (2009).","journal-title":"Cancer Biother. Radiopharm."},{"issue":"8","key":"98757_CR37","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1007\/s00259-022-05775-z","volume":"49","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 49(8), 2774\u20132785 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:14:32Z","timestamp":1745543672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98757"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98757-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14431"}}